Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 39 Carcinoma, Non-Small-Cell Lung 30 Esophageal Squamous Cell Carcinoma 23 Carcinoma, Hepatocellular 21 Triple Negative Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 17 Breast Neoplasms 17 Advanced Solid Tumor 17 Stomach Neoplasms 14 Melanoma 14 Small Cell Lung Carcinoma 13 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 12 Neoplasms 10 Carcinoma, Transitional Cell 10 Carcinoma, Renal Cell 10 Recurrence 9 Head and Neck Neoplasms 8 Solid Tumor 7 Sarcoma 7 Neoplasm Metastasis 7 Liver Neoplasms 7 Urinary Bladder Neoplasms 5 Rectal Neoplasms 5 Esophageal Neoplasms 5 Advanced Solid Tumors 5 Pancreatic Neoplasms 4 Nasopharyngeal Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4

Interventions

Specimen Handling 2 Nivolumab 2 toripalimab 1 talimogene laherparepvec 1 pembrolizumab 1 bicalutamide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Ipilimumab 1 Imiquimod 1 Fluorescein 1 CTLA-4 Antigen 1 Biopsy 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Paget Disease, Extramammary × toripalimab × Clear all

NCT06791070 2025-01-24

RC48&J for EPD

Fujian Medical University Union Hospital

Phase 2 Recruiting

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡